# Bright Minds Biosciences Inc.: Form 20-F for the period ended Sep 30, 2022

- Company: [Bright Minds Biosciences Inc.](/companies/drug.md) (CIK 1827401)
- Form: 20-F
- Filed: 2022-12-29
- Accepted by EDGAR: Dec 29, 2022, 16:42 ET
- Period: 2022-09-30
- Accession: 0001062993-22-024547
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1827401/000106299322024547/form20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1827401/000106299322024547/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Income tax | 12 months, 2021-10-01 to 2022-09-30 | CAD 0 | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2021-10-01 to 2022-09-30 | −CAD 15.0m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months, 2021-10-01 to 2022-09-30 | −CAD 1.21 | ifrs-full:DilutedEarningsLossPerShare |
| Operating cash flow | 12 months, 2021-10-01 to 2022-09-30 | −CAD 13.6m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | at 2022-09-30 | CAD 11.6m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2022-09-30 | CAD 11.9m | ifrs-full:CurrentAssets |
| Total assets | at 2022-09-30 | CAD 12.1m | ifrs-full:Assets |
| Current liabilities | at 2022-09-30 | CAD 1.5m | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2022-09-30 | CAD 1.5m | ifrs-full:Liabilities |
| Shareholders' equity | at 2022-09-30 | CAD 10.5m | ifrs-full:Equity |
| Shares outstanding | at 2022-09-30 | 17,592,359 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1827401/000106299322024547/form20f.htm

Filed Dec 29, 2022.
Source: SEC EDGAR, the filing index for accession 0001062993-22-024547. Last ingested by Listed: Nov 2, 2026, 18:24 ET. No prices; not investment advice.